Corbus Pharma reports CRB-701 Phase 1/2 ORR 47.6% HNSCC, 55.6% mUC at ESMO25

Corbus Pharmaceuticals Holdings, Inc.

3.6 mg/kg dose: ORR 47.6% in HNSCC (n=21), 37.5% in cervical cancer (n=16), 55.6% in mUC (n=9).
No grade 4/5 treatment-related AEs; low discontinuation rate (6.0%) and peripheral neuropathy (8.4% Grade 1/2).
Responses seen regardless of Nectin-4, HPV, or PD-L1 status; median prior therapies = 3.
Company plans FDA meeting in 2025 and registrational studies by mid-2026.
Data presented at ESMO25 from 167 patients; 122 evaluable for efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.